Research programme: liver X receptor modulators - Phenex Pharmaceuticals

Drug Profile

Research programme: liver X receptor modulators - Phenex Pharmaceuticals

Alternative Names: PX L493; PX L603

Latest Information Update: 27 Feb 2017

Price : $50

At a glance

  • Originator Phenex Pharmaceuticals
  • Class Hepatoprotectants
  • Mechanism of Action Liver X receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-alcoholic fatty liver disease
  • Discontinued Atherosclerosis; Hypercholesterolaemia

Most Recent Events

  • 11 Nov 2016 Pharmacodynamics data from preclinical studies in non-alcoholic steatohepatitis presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
  • 11 Nov 2016 Preclinical trials in Non-alcoholic fatty liver disease in Germany (PO)
  • 22 Sep 2010 Discontinued - Preclinical for Atherosclerosis in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top